Journal Article

DKFZ-2026-01185

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Outcome of patients with lung cancer treated with stereotactic body radiotherapy for bone oligometastases - a European multicenter cohort study.

Schäfer, S. ; Seiler, I. ; Balermpas, P. ; von Wachter, C. ; Loi, M. ; Greto, D. ; Schunn, A. S. ; Drabke, S. ; Klischies, K. ; Wittenstein, O. ; Willner, J. ; Lohaus, F.DKFZ* ; Kästner, L. ; Meents, J. ; Bank, P. ; Slavik, M. ; Burkon, P. ; Partl, R. ; Müller, J. A. ; Dzierma, Y. ; Mader, T. ; Trommer, M. ; Gkika, E. ; Rühle, A. ; Guckenberger, M. ; Moustakis, C. ; Brunner, T. ; Blanck, O. ; Boda-Heggemann, J. ; Nicolay, N. H. ; Nägler, F.

2026
BioMed Central London

Abstract: Metastasis-directed radiotherapy is of increasing importance in the multidisciplinary management of oligometastatic non-small cell lung cancer (NSCLC), but outcome patterns for stereotactic body radiotherapy (SBRT) of bone oligometastases (BoM) remain insufficiently defined. We aimed to determine oncological outcomes and prognostic factors of SBRT for BoM of NSCLC.Patients with NSCLC treated with SBRT for < 5 BoM between 2010 and 2024 at 15 European cancer centers were retrospectively analyzed. Outcomes included freedom from local recurrence (FFLR), progression-free survival (PFS), overall survival (OS), and adverse events.With a median follow-up of 14 months (IQR: 7-24 months), 85 patients with 111 treated BoM were analyzed. The 2-year FFLR was 87.2% (95%-CI: 73.3%-94.1%). The 1-/2-year PFS for singular BoM was 60.1% (CI: 44.6%-72.5%)/ 39.9% (CI: 24.6%-54.8%), while for 2-3 BoM they amounted to 10.2% (95%-CI: 0.6%-35.8%) and 0%. In multivariable analysis, less favorable outcome for OS and PFS was associated with larger BoM (HR 1.003; p < 0.01 and HR 1.005, p < 0.001) and increased number of treated BoM (HR 1.72; p = 0.03 and HR 1.93; p < 0.01). Treatment was well tolerated, with fracture rates of 5.4% and no grade 4 and 5 adverse events.This multicenter cohort analysis revealed that SBRT of BoM from NSCLC appears to be an effective and well-tolerated treatment. Presence of singular BoM was a favorable prognostic factor. Prospective studies are needed to confirm these findings and to determine the role of SBRT in the multidisciplinary management of oligometastases.

Keyword(s): Humans (MeSH) ; Radiosurgery: mortality (MeSH) ; Radiosurgery: methods (MeSH) ; Lung Neoplasms: pathology (MeSH) ; Lung Neoplasms: radiotherapy (MeSH) ; Lung Neoplasms: mortality (MeSH) ; Male (MeSH) ; Female (MeSH) ; Aged (MeSH) ; Retrospective Studies (MeSH) ; Bone Neoplasms: secondary (MeSH) ; Bone Neoplasms: radiotherapy (MeSH) ; Bone Neoplasms: mortality (MeSH) ; Carcinoma, Non-Small-Cell Lung: radiotherapy (MeSH) ; Carcinoma, Non-Small-Cell Lung: pathology (MeSH) ; Carcinoma, Non-Small-Cell Lung: mortality (MeSH) ; Carcinoma, Non-Small-Cell Lung: secondary (MeSH) ; Middle Aged (MeSH) ; Aged, 80 and over (MeSH) ; Prognosis (MeSH) ; Survival Rate (MeSH) ; Europe (MeSH) ; Follow-Up Studies (MeSH) ; Bone metastases ; Lung cancer ; MDT ; Metastasis-directed therapy ; Oligometastasis ; SBRT ; Stereotactic body radiotherapy ; Stereotactic radiotherapy

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Dresden (DD01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; ; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; DOAJ Seal ; Ebsco Academic Search ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---